The Weekly Recap 7/10/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, receive regulatory approvals, appoint new executives, and much more on the road to LSI Europe ‘26 in Barcelona (September 28 - October 1).

52 North

Granted its first U.S. patent, strengthening its IP foundation. The company’s proprietary Aster™ platform uses lateral flow technology to enable the measurement of both cell-based and soluble biomarkers from a single sample, in a rapid, easy-to-use and portable format.

ARC Medical

Announced positive clinical progress for its JOCOAT™ and IPCOAT™ surgical adhesion barrier programs, including encouraging expanded access results and continued advancement of clinical trials. JOCOAT demonstrated improved joint mobility with a favorable safety profile in orthopedic patients, while IPCOAT showed no new or recurrent adhesions in an expanded access gynecologic case, with pivotal clinical studies for both programs now underway.

Echo IQ

Secured A$110M through an institutional placement to fund its next phase of growth in the U.S. The proceeds will be directed toward U.S. commercial expansion and deployment of the company's EchoSolv platform, development of pipeline cardiovascular AI products spanning pulmonary hypertension, hypertrophic cardiomyopathy, mitral regurgitation, and cardio-oncology indications, and pursuit of strategic growth opportunities.

EndoShunt Medical

Welcomed LSI Alumni Duane Mancini as a Board Observer. Mancini brings extensive experience supporting medtech companies from early concept through commercial and strategic success, including time as CEO of Project Medtech and Managing Partner of PM Ventures.

Flosonics

Secured a strategic investment from Denka through its corporate venture capital fund operated with Pegasus Tech Ventures. The investment will support expansion of the company’s FloPatch wearable wireless Doppler ultrasound platform and accelerate broader access to hemodynamic assessment for critically ill patients, including those with sepsis.

KIFFIK Biomedical

Appointed Mark Vreeke as Chief Technology Officer. Vreeke brings more than three decades of technology, biosensor, and medical device leadership experience and looks to help advance the platform capabilities enabled by access to interstitial fluid and the biological insights that access can create.

Materna Medical

Closed its $5M B3 financing round, led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with continued support from existing investors. The funding will support completion of the EASE pivotal trial, expansion of Milli^® channel access ahead of the anticipated launch of the Ellora™ Obstetrical System, and growth of commercial manufacturing capabilities.

Onera Health

Awarded the Red Dot Award: Product Design 2026 for the company’s Onera hPSG^® because of the sensor’s innovative design, advanced functionality, and user-centric engineering. Onera hPSG stood out for outstanding functionality, striking aesthetics, and a thoughtful user experience.

Paradromics

Welcomed LSI Alumni William Marks as its new Chief Clinical Officer, bringing leadership experience from UCSF, Medtronic’s global deep brain stimulation business, and Verily. Following the first human implantation of the Connexus^® BCI, Marks will help guide the company’s clinical strategy as it advances toward broader clinical adoption.

Penumbra

Secured a CE mark for its Red 72 Silver Label and Red 72 Silver Label with Sendit technology products. The Red 72 Silver Label devices are reperfusion catheters designed for acute ischaemic stroke, while the new Red 72 Silver Label with Sendit technology is designed to minimize ledge effect, simplify preparation, and ease delivery in LVO stroke. 

S2N Health

Welcomed Sushma Rajagopalan and LSI Alumni Steven Schaefer to its Board of Directors and closed a convertible note financing round with participation from new and existing investors. The funding will support continued development of the company’s AI-powered commercial intelligence platforms, product innovation, and go-to-market expansion across the medtech industry.

Salvia BioElectronics

Appointed Jill Schiaparelli as its Board Chair. With nearly three decades of leadership across medical devices, neuromodulation, and commercial strategy, Schiaparelli brings deep U.S. market expertise and a proven track record scaling and growing innovative medical technology companies. 

Solaris Endovascular

Welcomed Rowan Hettel as Chief Technology Officer and David Stack as Director. Together, they bring decades of experience in medical device innovation, product development, strategic leadership, and value creation that will help guide the company through its next phase of growth.

Solenic Medical

Received FDA IDE approval to initiate a pivotal clinical trial of the SOLA-2™ Alternating Magnetic Field System in patients with periprosthetic joint infections following the close of its $6.6M Series B in April. SOLA-2 leverages the company’s proprietary AMF technology to precisely heat the outer surface of metallic implants and disrupt bacterial biofilms, the underlying driver of implant infections, avoiding implant removal.

SpinaFX

Appointed John Soloninka as its CEO following his leadership in achieving key regulatory milestones for the company as COO, CTO, and CSO. Soloninka brings more than 30 years of health technology experience, including founding and financing multiple companies and investment funds, raising over $50M for startups, and helping secure more than $425M in public-private research funding.

Star51

Welcomed LSI Alumni Anna Hildebrand to the team as Inaugural Principal. Hildebrand joins the team after spending time at IAG Capital Partners, where she invested in early-stage medtech, and looks to help close the gap between viable business ideas and successful companies.

Tensive

Appointed Peter Crosby as Chairman of its Board of Directors, bringing more than 40 years of leadership experience across the medical device industry. A member of the founding team at Cochlear, Crosby also led Mainstay Medical through its Euronext IPO, CE marking, and FDA approval, and has raised more than $200M in public and private capital while helping bring numerous implantable devices to market.

United Therapeutics

Received FDA PMA approval for its LungFX perfusion device. By utilizing ex vivo lung perfusion (EVLP), the system allows clinical teams to thoroughly evaluate and preserve donor lungs outside the human body before transplantation.

Xeltis

Performed the first commercial implantation of aXess™. aXess is an implantable blood vessel for hemodialysis vascular access, initially serving as a scaffold ready for cannulation before gradually transforming into each patient’s own living vessel for long-term, reliable vascular access.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.